Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03515993 | Follow-up in Gynecological Cancer Survivors | active not recruiting | — | 1,100 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | May 12, 2026 | clinicaltrials |
| NCT03933826 | CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer(CISTO) | active not recruiting | — | 570 | University of WashingtonOTHER |
| 1 |
| May 12, 2026 |
| clinicaltrials |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | active not recruiting | Phase 1 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05029258 | Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer(Bio-CHECC) | active not recruiting | — | 30 | University of ManchesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05592665 | PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology(PRO-VISION) | active not recruiting | N/A | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03601455 | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | active not recruiting | Phase 2 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04262154 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | active not recruiting | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04384770 | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | active not recruiting | — | 179 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer(iNNOVATE) | active not recruiting | Phase 1 | 18 | Virginia Commonwealth UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06195150 | Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer(ITHORinVHL) | active not recruiting | — | 3 | IRCCS San RaffaeleOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06318871 | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | active not recruiting | Early Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT01368588 | Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 2,590 | Radiation Therapy Oncology GroupNETWORK | 6 | May 8, 2026 | clinicaltrials |
| NCT03637543 | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 2 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03932409 | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer(FIERCE) | active not recruiting | Phase 1 | 45 | University of OklahomaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05826509 | SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer(SUGAR) | active not recruiting | Phase 2 | 240 | Institut Claudius RegaudOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06116253 | Advanced Diffusion Imaging in Renal Cancer Patients | active not recruiting | N/A | 39 | NYU Langone HealthOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04713618 | Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy(GEORGIA) | active not recruiting | — | 72 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05154994 | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma(RESOLVE) | active not recruiting | Phase 1 | 9 | University of UtahOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06790004 | Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy)(LPSvsLPT) | active not recruiting | — | 700 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
| NCT00579072 | The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older | active not recruiting | — | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate(DASL-HiCaP) | active not recruiting | Phase 3 | 1,100 | University of SydneyOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06212583 | High-Risk Metachronous Oligometastatic Prostate Cancer Trial(KNIGHTS) | active not recruiting | Phase 2 | 88 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01411345 | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial(MAPS) | active not recruiting | N/A | 37 | University of MiamiOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04022343 | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | active not recruiting | Phase 2 | 22 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04430699 | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | active not recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | active not recruiting | Phase 3 | 747 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 5, 2026 | clinicaltrials |
| NCT04620603 | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | active not recruiting | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | active not recruiting | Phase 3 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 27 | May 5, 2026 | clinicaltrials |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA) | active not recruiting | Phase 1 / Phase 2 | 29 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT01737619 | PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer | active not recruiting | N/A | 101 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT03757949 | Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery | active not recruiting | Phase 3 | 203 | SWOG Cancer Research NetworkNETWORK | 1 | May 4, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04753086 | Patient Related Outcomes for Gynecologic Radiation Oncology(PRO-GRO) | active not recruiting | — | 100 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04927650 | Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening | active not recruiting | — | 2,556 | University of California, San FranciscoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05851365 | Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer | active not recruiting | Early Phase 1 | 1 | Robert Flavell, MD, PhDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06651632 | WATER IV Prostate Cancer(WATER IV PCa) | active not recruiting | N/A | 280 | PROCEPT BioRoboticsINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT04194554 | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer(ASCLEPIuS) | active not recruiting | Phase 1 / Phase 2 | 102 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | active not recruiting | Phase 3 | 520 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 1, 2026 | clinicaltrials |
| NCT05322356 | Prostate Interstitial Brachytherapy With I125 Implant With Target Dose Supplementation in the Tumor Volume Guided by TRINITY® PERINE 3D System(FOCUS-BOOST) | active not recruiting | N/A | 15 | University Hospital, GrenobleOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06180733 | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer(PAM-II) | active not recruiting | Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01068249 | Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2026source: clinicaltrials